Journal of Lipid Research, Vol 38, 1361-1373, Copyright © 1997 by Lipid Research, Inc.

ARTICLES

Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease, and receptor binding of low density lipoproteins

EH Ludwig, PN Hopkins, A Allen, LL Wu, RR Williams, JL Anderson, RH Ward, JM Lalouel and TL Innerarity
Department of Human Genetics and Howard Hughes Medical Institute, University of Utah, Salt Lake City 84112, USA.

To search for unique mutations in the apolipoprotein B (apoB) gene that disrupt the binding of LDL to its receptor and cause hypercholesterolemia, we examined more than 800 patients with high LDL cholesterol levels and/or coronary artery disease (CAD). Analysis of patient DNA by single-strand conformation polymorphism and allele- specific oligonucleotide hybridization of the sequence surrounding the putative receptor- binding domain of apoB (amino acid positions 2965 to 3534) revealed seven variations. LDL from heterozygotes with either Arg 3500 Gln or Arg 3531 Cys bound defectively with the LDL receptor in competitive binding assays. The Arg 3500 Gln substitution was statistically more prevalent in patients with hypercholesterolemia (P = 0.0003). Total cholesterol and LDL-cholesterol were significantly higher (P< 0.0004) in 34 apoB 3500 Gln carriers than in the controls. The allele encoding the Arg 3531 Cys substitution was more prevalent (0.8%) in the CAD group (P = 0.05) than in the controls. A Ser 3252 Gly variant was statistically more prevalent in the hypercholesterolemic group (P = 0.03), but LDL with this mutation had normal LDL receptor- binding activity. The other four variants identified (Leu 3350 Leu, Gln 3405 Glu, Val 3396 Met, and Ser 3455 Arg) were not associated with defective LDL-receptor binding, hypercholesterolemia, or CAD, nor were the apoB mutations associated with elevated lipid levels in family members. The surprising result that only two mutations of apoB in the receptor-binding domain (Arg 3500 Gln and Arg 3531 Cys) were associated with defective LDL binding, hypercholesterolemia, or CAD is in stark contrast with familial hypercholesterolemia, where nearly 150 mutations of the LDL receptor have been described that disrupt its function. This study strongly suggests that a limited number of mutations of apoB markedly influence LDL binding to its receptor.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Benn, B. G. Nordestgaard, J. S. Jensen, and A. Tybjaerg-Hansen Polymorphisms in Apolipoprotein B and Risk of Ischemic Stroke J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3611 - 3617. [Abstract] [Full Text] [PDF]

				M. A. Austin, C. M. Hutter, R. L. Zimmern, and S. E. Humphries Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review Am. J. Epidemiol., September 1, 2004; 160(5): 407 - 420. [Abstract] [Full Text] [PDF]

				M. A. Austin, C. M. Hutter, R. L. Zimmern, and S. E. Humphries Familial Hypercholesterolemia and Coronary Heart Disease: A HuGE Association Review Am. J. Epidemiol., September 1, 2004; 160(5): 421 - 429. [Abstract] [Full Text] [PDF]

				J.-P. Rabes, M. Varret, M. Devillers, P. Aegerter, L. Villeger, M. Krempf, C. Junien, and Catherine Boileau R3531C Mutation in the Apolipoprotein B Gene Is Not Sufficient to Cause Hypercholesterolemia Arterioscler. Thromb. Vasc. Biol., October 1, 2000; 20 (10): e76 - e82. [Abstract] [Full Text] [PDF]

				L. Beghin, N. Duhal, P. Poulain, P. Hauw, B. Lacroix, J.-M. Lecerf, J.-P. Bonte, J.-C. Fruchart, and G. Luc Measurement of apolipoprotein B concentration in plasma lipoproteins by combining selective precipitation and mass spectrometry J. Lipid Res., July 1, 2000; 41(7): 1172 - 1176. [Abstract] [Full Text]

				B. Raungaard, F. Heath, P. S. Hansen, J. U. Brorholt-Petersen, H. K. Jensen, and O. Fargeman Flow Cytometric Assessment of LDL Ligand Function for Detection of Heterozygous Familial Defective Apolipoprotein B-100 Clin. Chem., February 1, 2000; 46(2): 224 - 233. [Abstract] [Full Text] [PDF]

				F. M. van 't Hooft, S. Jormsjö, B. Lundahl, P. Tornvall, P. Eriksson, and A. Hamsten A functional polymorphism in the apolipoprotein B promoter that influences the level of plasma low density lipoprotein J. Lipid Res., September 1, 1999; 40(9): 1686 - 1694. [Abstract] [Full Text]

				E. Fisher, H. Scharnagl, M. M. Hoffmann, K. Kusterer, D. Wittmann, H. Wieland, W. Gross, and W. Marz Mutations in the Apolipoprotein (apo) B-100 Receptor-binding region: Detection of apo B-100 (Arg3500->Trp) Associated with Two New Haplotypes and Evidence That apo B-100 (Glu3405->Gln) Diminishes Receptor-mediated Uptake of LDL Clin. Chem., July 1, 1999; 45(7): 1026 - 1038. [Abstract] [Full Text] [PDF]

				L. Haddad, I. N. M. Day, S. Hunt, R. R. Williams, S. E. Humphries, and P. N. Hopkins Evidence for a third genetic locus causing familial hypercholesterolemia: a non-LDLR, non-APOB kindred J. Lipid Res., June 1, 1999; 40(6): 1113 - 1122. [Abstract] [Full Text]

				C. R. Pullinger, D. Gaffney, M. M. Gutierrez, M. J. Malloy, V. N. Schumaker, C. J. Packard, and J. P. Kane The apolipoprotein B R3531C mutation: characteristics of 24 subjects from 9 kindreds J. Lipid Res., February 1, 1999; 40(2): 318 - 327. [Abstract] [Full Text]

				D. Gaffney, C. Pullinger, J. Kane, J. R. Schaefer, M. Herzum, B. Maisch, A. Tybjarg-Hansen, and B. G. Nordestgaard Association of Mutations in the Apolipoprotein B Gene with Hypercholesterolemia and the Risk of Ischemic Heart Disease N. Engl. J. Med., November 26, 1998; 339(22): 1640 - 1642. [Full Text]

				A. Tybjarg-Hansen, R. Steffensen, H. Meinertz, P. Schnohr, and B. G. Nordestgaard Association of Mutations in the Apolipoprotein B Gene with Hypercholesterolemia and the Risk of Ischemic Heart Disease N. Engl. J. Med., May 28, 1998; 338(22): 1577 - 1584. [Abstract] [Full Text] [PDF]